Persistent Asset's Q2 Investments
Persistent Asset Partners Discloses Q2 Stock Buys Across Five Companies
Key Points
BTG: 61.40% of B2Gold stock is owned by institutional investors and hedge funds, underscoring a high level of institutional ownership beyond Persistent Asset Partners' new stake.
BTG: In its coverage, Royal Bank Of Canada trimmed its price target on B2Gold from $5.75 to $5.00 and kept a sector perform rating, while Scotiabank upgraded B2Gold to sector outperform.
MKSI: Nearly all ownership is institutional, with 99.79% of MKSI stock held by institutional investors; the stock opened at $310.73 with a 50-day moving average of $345.69 and a 200-day moving average of $292.67.
FSLR: First Solar shows very high institutional ownership at 92.08%, and several analysts issued updated targets: Wells Fargo moved to a $313 target, Barclays to $279, and Mizuho to $324, alongside Oppenheimer's market-perform stance.
NRIX: Bank of New York Mellon Corp opened a new NRIX position in Q2 worth about $6.61 million; NRIX has a market cap of about $2.81 billion, a negative P/E of -7.84, a beta of 1.79, and traded with a 27.05 opening price (50-day MA ~22.33, 200-day MA ~18.32).
Persistent Asset Partners Ltd expanded its portfolio in Q2, picking up new or larger positions in five companies across mining, semiconductors, solar energy, and biotech. The firm's biggest move was a $1.94 million increase in 4D Molecular Therapeutics (FDMT), adding 145,585 shares, according to Ticker Report.
In total, the firm added stakes in B2Gold (BTG), MKS Instruments (MKSI), First Solar (FSLR), 4D Molecular Therapeutics (FDMT), and Nurix Therapeutics (NRIX). The purchases range from about $702,000 in FSLR to nearly $1.94 million in FDMT, painting a picture of a firm spreading bets across growth sectors, according to Watchlist News.
Gold Mining and Chip Gear Bets Lead New Purchases
Persistent Asset Partners bought 208,812 shares of B2Gold (BTG) for roughly $781,000. BTG already has 61.40% of its stock held by institutional investors and hedge funds, per Ticker Report. Royal Bank of Canada recently cut its price target on BTG from $5.75 to $5.00, keeping a "sector perform" rating. Scotiabank went the other way, upgrading BTG to "sector outperform."
The firm also bought 3,577 shares of MKS Instruments (MKSI) for about $1.59 million. MKSI has some of the highest institutional ownership of any stock in its class — 99.79% of shares are held by institutions, according to Watchlist News. The stock opened at $310.73. Its 50-day moving average sits at $345.69, well above its 200-day average of $292.67.
First Solar Draws Analyst Attention Alongside New Stake
Persistent Asset Partners added 3,013 shares of First Solar (FSLR) worth about $702,000. FSLR carries 92.08% institutional ownership, making it one of the most institutionally held names in clean energy, per Ticker Report. Several Wall Street desks recently updated their price targets on the stock.
Wells Fargo set a $313 target on FSLR. Barclays moved to $279. Mizuho went higher, landing at $324. Oppenheimer took a more cautious "market perform" stance. The wide range of targets shows analysts are split on how much upside remains in solar after a volatile stretch for clean energy stocks.
Biotech Bets: FDMT Stake Grows, NRIX Position Opens Fresh
The firm's largest single move was adding 145,585 shares of 4D Molecular Therapeutics (FDMT) for about $1.94 million. FDMT shows very high institutional ownership, suggesting Persistent Asset Partners is joining a crowded but committed group of institutional backers, according to Ticker Report.
The firm also opened a brand-new position in Nurix Therapeutics (NRIX), buying 30,973 shares worth about $751,000. NRIX has a market cap of roughly $2.81 billion and a beta of 1.79, meaning it swings harder than the broader market. The stock carries a negative P/E ratio of -7.84, typical for early-stage biotech. NRIX opened at $27.05, well above its 50-day moving average of $22.33 and its 200-day average of $18.32, per Watchlist News.
Big Institutions Also Piling Into NRIX Alongside Persistent
Persistent Asset Partners is not alone in its new NRIX bet. Bank of New York Mellon Corp also opened a fresh position in Nurix Therapeutics during Q2, buying in at roughly $6.61 million — nearly nine times the size of Persistent's stake, according to Watchlist News. That level of institutional activity signals growing confidence in the biotech's pipeline.
Across all five new positions, Persistent Asset Partners committed roughly $5.76 million in Q2. The picks span gold mining, precision manufacturing tools, solar panels, and two different biotech platforms. The breadth of the buys suggests a diversification strategy rather than a concentrated sector thesis.
Sentiment
Mostly PositivePublishers
24
Articles
16
Reach
40
